Crossmark Global Holdings, Inc. - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 567 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Crossmark Global Holdings, Inc. ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$878
-20.2%
12,647
-3.7%
0.02%
-16.7%
Q2 2023$1,100
+1.2%
13,136
-10.3%
0.02%
-7.7%
Q1 2023$1,087
+16.9%
14,644
+30.6%
0.03%
+13.0%
Q4 2022$930
-99.8%
11,216
+437.9%
0.02%
+43.8%
Q3 2022$592,000
-17.1%
2,085
+1.3%
0.02%
-15.8%
Q2 2022$714,000
-11.2%
2,058
+10.8%
0.02%
+5.6%
Q1 2022$804,000
-19.0%
1,858
-3.1%
0.02%
-18.2%
Q4 2021$992,000
-56.0%
1,918
-58.7%
0.02%
-58.5%
Q3 2021$2,252,000
+26.9%
4,648
+17.9%
0.05%
+26.2%
Q2 2021$1,775,000
+8.8%
3,943
-7.7%
0.04%
+5.0%
Q1 2021$1,632,000
+18.3%
4,273
-1.6%
0.04%
+14.3%
Q4 2020$1,379,000
+30.2%
4,343
+1.6%
0.04%
+16.7%
Q3 2020$1,059,000
-2.9%
4,273
+3.4%
0.03%
-6.2%
Q2 2020$1,091,000
+47.8%
4,133
+6.2%
0.03%
+23.1%
Q1 2020$738,000
-11.8%
3,893
+2.1%
0.03%
+13.0%
Q4 2019$837,000
+26.6%
3,813
+12.8%
0.02%
+21.1%
Q3 2019$661,000
-10.4%
3,380
-4.5%
0.02%
-9.5%
Q2 2019$738,000
+2.2%
3,541
-2.6%
0.02%
+5.0%
Q1 2019$722,000
+45.9%
3,635
+6.2%
0.02%
+33.3%
Q4 2018$495,000
-57.6%
3,423
-40.2%
0.02%
-50.0%
Q3 2018$1,168,000
+11.7%
5,723
-19.1%
0.03%
+7.1%
Q2 2018$1,046,000
-0.1%
7,070
+2.0%
0.03%
+3.7%
Q1 2018$1,047,000
-4.1%
6,930
-17.8%
0.03%
+3.8%
Q4 2017$1,092,000
+7.3%
8,430
+0.1%
0.03%0.0%
Q3 2017$1,018,0000.0%8,4200.0%0.03%0.0%
Q3 2016$1,018,0008,4200.03%
Other shareholders
BIO-TECHNE CORP shareholders Q4 2021
NameSharesValueWeighting ↓
Ownership Capital B.V. 972,263$308,742,0004.35%
Sandhill Capital Partners LLC 138,864$44,096,0004.03%
STONE RUN CAPITAL, LLC 27,350$8,685,0003.45%
DF DENT & CO INC 925,823$293,995,0003.42%
Brown Capital Management 1,498,233$475,764,0003.29%
MAIRS & POWER INC 848,081$269,308,0002.99%
Summit Creek Advisors LLC 64,179$20,380,0002.62%
GENEVA CAPITAL MANAGEMENT LLC 402,958$127,959,0002.17%
Aristotle Atlantic Partners, LLC 86,993$27,625,0002.13%
CROWN ADVISORS MANAGEMENT, INC. 8,000$2,540,0001.82%
View complete list of BIO-TECHNE CORP shareholders